YS Biopharma (YS) News Today → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free YS Stock Alerts $0.78 +0.01 (+1.30%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officerprnewswire.com - May 7 at 4:20 PMWith 80% ownership, YS Biopharma Co., Ltd. (NASDAQ:YS) insiders have a lot riding on the company's futurefinance.yahoo.com - May 7 at 9:13 AMYS Biopharma Co., Ltd.: YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rulefinanznachrichten.de - April 29 at 5:14 PMYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Ruleprnewswire.com - April 29 at 8:00 AMFY2024 EPS Estimates for YS Biopharma Co., Ltd. (NASDAQ:YS) Lowered by Analystmarketbeat.com - April 25 at 7:53 AMYS Biopharma Co., Ltd. (NASDAQ:YS) Q3 2024 Earnings Call Transcriptfinance.yahoo.com - April 22 at 12:43 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024finanznachrichten.de - April 19 at 12:56 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024finanznachrichten.de - April 19 at 12:56 PMYS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024markets.businessinsider.com - April 19 at 12:56 PMYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024prnewswire.com - April 19 at 7:00 AMYS Biopharma Co., Ltd.: YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccinefinanznachrichten.de - April 18 at 9:35 AMYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccineprnewswire.com - April 18 at 8:00 AMYS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024finance.yahoo.com - April 16 at 10:39 AMChinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitormsn.com - April 9 at 8:09 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccinefinanznachrichten.de - April 9 at 10:09 AMYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccinefinance.yahoo.com - April 9 at 10:09 AMYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccineprnewswire.com - April 9 at 8:00 AMYS Biopharma Announces Full Repayment of US$40,000,000 Loan Facilityfinance.yahoo.com - April 3 at 10:46 AMTechnology and demographics affect hiring and pay strategiesmsn.com - March 28 at 4:38 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiariesfinanznachrichten.de - March 5 at 2:40 PMYS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiariesfinance.yahoo.com - March 5 at 9:39 AMYS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024finance.yahoo.com - February 22 at 9:10 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meetingfinanznachrichten.de - February 17 at 9:18 AMYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meetingfinance.yahoo.com - February 17 at 12:39 AMYS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meetingprnewswire.com - February 16 at 8:20 PMShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.finance.yahoo.com - February 16 at 7:33 PMShareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.prnewswire.com - February 16 at 5:36 PMYS Biopharma Announces Appointment of New Directorsfinance.yahoo.com - February 14 at 10:44 AMYS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governancefinance.yahoo.com - February 14 at 10:44 AMYS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governanceprnewswire.com - February 14 at 8:00 AMYS Biopharma Announces Appointment of New Directorsprnewswire.com - February 14 at 7:50 AMYS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.finance.yahoo.com - February 12 at 1:26 PMYS Biopharma Announces US$40 Million Private Placement Financingfinance.yahoo.com - February 9 at 7:03 AMShareholders of YS Biopharma Announce an Extraordinary General Meetingfinance.yahoo.com - February 8 at 9:02 PMYS Biopharma Co., Ltd.: YS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024finanznachrichten.de - January 24 at 7:14 AMYS Biopharma Announces Unaudited Financial Results for the First Half of Fiscal Year 2024finance.yahoo.com - January 22 at 6:56 PMYS Biopharma Announces Changes to its Board Committeesfinance.yahoo.com - January 8 at 10:24 AMYS Biopharma Says Fake Press Release Called for Extraordinary General Meetingmarketwatch.com - December 20 at 7:15 PMYS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meetingfinance.yahoo.com - December 20 at 7:15 PMYS Biopharma Co., Ltd. to Hold Extraordinary General Meeting on December 28, 2023finance.yahoo.com - December 20 at 2:15 PMLantheus and Point Biopharma shares drop on prostate cancer treatment datamsn.com - December 18 at 12:15 PMWhen Can We Expect A Profit From YS Biopharma Co., Ltd. (NASDAQ:YS)?finance.yahoo.com - November 15 at 8:30 AMNoble Capital Markets Initiates Coverage of YS Biopharma (YS) with Outperform Recommendationmsn.com - November 14 at 11:02 PMBiopharma Has No Choice But To Comply With Price Controlsforbes.com - November 14 at 1:00 PMYS Biopharma Announces Completion of Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccinefinance.yahoo.com - October 31 at 10:03 AMYS Biopharma receives Nasdaq notice regarding minimum bid price requirementmsn.com - October 26 at 10:25 AMYS Biopharma Announces Receipt of Nasdaq Noticefinance.yahoo.com - October 26 at 10:25 AMUPDATE - Diamond Equity Research Releases Update Note on YS Biopharma Co., Ltd. (NASDAQ: YS)finance.yahoo.com - October 10 at 8:29 AMYS Biopharma enrols first subject in PIKA Rabies Vaccine studymsn.com - September 28 at 9:18 AMYS Biopharma Announces First Subject Enrollment in Pivotal Phase 3 Clinical Trial of PIKA Rabies Vaccinefinance.yahoo.com - September 26 at 9:24 AM Get YS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter. Email Address The new financial threat that could wipe out millions… (Ad)During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks. Pay close attention to this important video YS Media Mentions By Week YS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YS News Sentiment▼0.730.38▲Average Medical News Sentiment YS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YS Articles This Week▼21▲YS Articles Average Week Get YS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for YS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rallybio News Today Landos Biopharma News Today MediciNova News Today SCYNEXIS News Today Viveon Health Acquisition News Today Carisma Therapeutics News Today vTv Therapeutics News Today Journey Medical News Today Mural Oncology News Today Assembly Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024Altimetry[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding YS Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
